Marketing-authorisation holder · United States
Modern Veterinary Therapeutics LLC
36 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
36 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 36
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BOVICAM 2020 mg / ml · Solution | Meloxicam | Canada | Marketed | 2023 |
| CEPESEDAN10 mg / ml · Solution | Detomidine | Canada | Marketed | 2010 |
| CEPETOR1 mg / ml · Solution | Medetomidine | Canada | Marketed | 2010 |
| CLOPROSTENOL VEYX0.25 mg / ml · Solution | Cloprostenol | Canada | Marketed | 2014 |
| CLOPROSTENOL VEYX SW175 mcg / 2 ml · Solution | Cloprostenol | Canada | Marketed | 2017 |
| DEXVETIDINE0.5 mg / ml · Solution | Dexmedetomidine | Canada | Marketed | 2019 |
| EMEQUEL10 mg / ml · Solution | Maropitant | Canada | Authorised | |
| ENROTRON 5050 mg / ml · Solution | Enrofloxacin | Canada | Marketed | 2021 |
| EPRINOVET5 mg / ml · Solution | Eprinomectin | Canada | Authorised | |
| FLUTREXIN50 mg / ml · Solution | Flunixin | Canada | Marketed | 2026 |
| GONAVET54 mcg / ml · Solution | Gonadorelin | Canada | Marketed | 2023 |
| HYMATIL300 mg / ml · Solution | Tilmicosin | Canada | Marketed | 2015 |
| KETOPROFEN V100 mg / ml · Solution | Ketoprofen | Canada | Marketed | 2016 |
| MAPRELIN XP-1075 mcg / ml · Solution | Peforelin | Canada | Marketed | 2020 |
| MOXICLOPRID 1040 mg / 0.4 ml + 10 mg / 0.4 ml · Solution | Imidacloprid, Moxidectin | Canada | Not marketed | 2023 |
| MOXICLOPRID 100400 mg / 4 ml + 100 mg / 4 ml · Solution | Imidacloprid, Moxidectin | Canada | Not marketed | 2023 |
| MOXICLOPRID 1880 mg / 0.8 ml + 8 mg / 0.8 ml · Solution | Imidacloprid, Moxidectin | Canada | Not marketed | 2023 |
| MOXICLOPRID 20100 mg / 0.4 ml + 25 mg / 1 ml · Solution | Imidacloprid, Moxidectin | Canada | Not marketed | 2023 |
| MOXICLOPRID 55250 mg / 2.5 ml + 62.5 mg / 2.5 ml · Solution | Imidacloprid, Moxidectin | Canada | Not marketed | 2023 |
| MOXICLOPRID 940 mg / 0.4 ml + 4 mg / 0.4 ml · Solution | Imidacloprid, Moxidectin | Canada | Not marketed | 2023 |
| ORTHOXICAM5 mg / ml · Solution | Meloxicam | Canada | Authorised | |
| RESPIPULMIN0.025 mg / ml · Syrup | Clenbuterol | Canada | Marketed | 2012 |
| RESPIRAM20 mg / ml · Solution | Doxapram | Canada | Not marketed | 2010 |
| RESPOTIL250 mg / ml · Solution | Tilmicosin | Canada | Marketed | 2021 |
| REVERTOR5 mg / ml · Solution | Atipamezole | Canada | Marketed | 2010 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 36 | 36 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.